Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 663-668

  Massidda, Bruno ^a,b   Fenu, Maria Antonietta ^a   Ionta, Maria Teresa ^a   Tronci, Miriam ^a   Foddi, Maria Restituta ^a   Montaldo, Cristiana ^a   Montaldo, Pier Luigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NONE   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Haemodynamic study

Indexed keywords

ANTHRACYCLINE; EPIRUBICIN; IRON; RAZOXANE; UBIDECARENONE;

ADULT; ARTICLE; BREAST CANCER; CARDIOGRAPHY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON OVERLOAD; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0031043204     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 10 enzimes, Cancer Treat Rep 60 (3): 223-224, 1976.
2. 10 on the adriamycin- induced cardiotoxicity in the isolated perfused rat heart. J Mol Cardiol 13: 741-752, 1981.
3. 10) in man. In: Biomedical and Clinical aspects of Coenzyme Q vol 5 (Folkers K and Yamamura Y Eds). Elservier Science Publisher B.V. (Biomedical Division) pp 241-245, 1986.
4. Basser RL, Sobal MM, Duggan G, Caban J, Rosenthal MA, Mihaly G, Green MD: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 12: 1659-1666, 1994.
5. Speyer JL, Green MD, Zeleninch-Jacquotte A, Wernz JC, Rev M, Sanger J, Kramer H, Ferrans V, Hochster H, Meyers M, Slum RH, Feit F, Attubato M, Burrows W, Muggia FM: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10: 117-127, 1992.
6. 10 to adriamycin treated patients. In: Biomedical and Clinical aspects of Coenzyme Q vol 5 (Folkers K and Yamamura Eds). Elsevier Science Publisher B.V. (Biomedical Division) pp 267-274, 1986.
7. 10 on ECG changes induced by doxorubicin (adriamycin). In: Biomedical and Clinical aspects of Coenzyme Q. Vol 5 (Folkers K and Yamamura Y Eds). Elsevier Science Publisher B. V. (Biomedical Division) pp 247-256, 1986.
8. 10 on the adriamycin-induced depression of myocardial contractility. In: Biomedical and Clinical aspects of coenzyme Q. Vol 2 (Yamamura Y, Folkers K and Ito Y Eds). Elsevier North Holland Biomedical Press, pp 225-230, 1980.
9. Schwartz RG, Mc Kenzie WD, Alexander J: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 82: 1109-1118, 1987.
10. Carrió I, Estorch M, Berná L, Germá JR, Alonso C, Ojeda B, De Andrés L, Lopez-Ponsa A, Martinez-Duncker C, Torres G: Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med 18: 806-812, 1991.
11. Mattar JA, et al: A clinical comparison between cardiac output measured by thermodilution versus noninvasivc thoracic electrical bioimpedance. Acute Care 12: 58, 1986.
12. Appel PL et al: Comparison of measurements of cardiac output by bioimpedance and thermodilution in severely ill surgical patients. Crit Care Med Vol 14: 933, 1986.
13. Bernstein DP: A new stroke volume equation for thoracic electrical bioimpedance: Theory and rationale. Crit Care Med Vol 14: 904, 1986.
14. Sramek BB: Noninvasive technique for measurement of cardiac output by means of electrical impedance. Proceedings of the 5th Int'l Conference on Electrical Bioimpedance. Tokyo, Japan, 39, 1981.
15. Yamashita J, Ogawa M, Shirakusa T: Plasma endothelin-1 as marker for doxorubicin cardiotoxicity. Int J Cancer 62 (5): 542-547, 1995.
16. Valls V, Castelluccio C, Fato R, Genova ML, Bovina C, Saez G, Marchetti M, Castelli GP, Lenaz G: Protective effect of exogenous coenzyme Q against damage by adriamycin in perfused rat liver. Biochem Mol Biol Int 33 (4): 633-642, 1994.
17. Hasinoff BB: The interaction of the cardioprotective agent ICRF-187: its hydrolysis product (ICRF-198) and other chelating agent with Fe and Cu ion complexes of adriamycin. Agents and Actions 26: 378-385, 1989.